John Diaz
MD
Chief of Gynecologic Oncology
Miami Cancer Institute

John P. Diaz, M.D., FACOG, FACS, is a board-certified gynecologic oncologist with a distinguished career in clinical care, academic leadership and research. He currently serves as chair of the Department of Obstetrics and Gynecology at Florida International University Herbert Wertheim College of Medicine and holds multiple leadership roles at Baptist Health South Florida, including chief of gynecologic oncology, director of robotic surgery and director of clinical research in gynecologic oncology.
Dr. Diaz earned his medical degree from the University of Miami Miller School of Medicine, where he was inducted into Iron Arrow, the university’s highest honor society. He completed his residency in obstetrics and gynecology at Jackson Memorial Hospital/University of Miami and went on to complete his fellowship in gynecologic oncology at Memorial Sloan Kettering Cancer Center in New York, where he received the Department of Surgery Chairman’s Award for Excellence in Clinical Research.
A surgical innovator, Dr. Diaz has helped pioneer novel procedures such as fertility-sparing radical trachelectomy for early-stage cervical cancer and sentinel lymph node mapping in gynecologic malignancies. He also performed Florida’s first uterine transposition procedure for a patient with gynecologic cancer, preserving reproductive potential in a groundbreaking approach. In addition, he was awarded a $1.7 million research grant to investigate novel therapeutics for the treatment of gynecologic cancers.
Dr. Diaz has authored numerous peer-reviewed publications, remains deeply committed to medical education and mentorship. His work reflects an enduring dedication to advancing women’s cancer care, surgical innovation and academic leadership on both a regional and national level.

Sessions

Register
General Session

Immunotherapy for All

Sunday, March 15, 2026
2:10 PM - 2:30 PM
General Session

Front-Line Metastatic Endometrial Cancer: Immunotherapy for All vs Molecular Profiling to Individualize Therapy – Immunotherapy Should Not Be an Empiric Selection

Sunday, March 15, 2026
2:10 PM - 2:55 PM
Back to top